Being tested
Dronabinol: improve symptoms or function in MS (type not specified)
Trial timeline
Trial start year. Dot size reflects participants where reported. Only trials that count towards the status are shown.
MS (type not specified) · Spasticity
Trials are running now and no controlled trial has a readable result yet.
- Trials
- 10
- Running now
- 1
- Controlled phase 2/3 trials
- 8
- People in controlled trials
- 1523
Deciding trials (phase 3): 0 met, 1 did not.
Other linked trials: 9
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Phase 3 · 2021 · Placebo-controlled · MSFT-NCT04984278
Phase 3 · 2020 · Placebo-controlled · MSFT-NCT04657666
Phase 3 · 2020 · Placebo-controlled · MSFT-NCT04203498
Phase 3 · 2018 · Placebo-controlled · MSFT-2018-000001-23
- Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Central Neuropathic Pain Related to Multiple Sclerosisdecides the statusMissed main goal
Phase 3 · 2007 · Placebo-controlled · MSFT-NCT00959218
Pain intensity during 16-weeks dronabinol and placebo treatment was reduced by 1.92 and 1.81 points without significant difference in between (p = 0.676).
Read by software from the paper's abstract - The Effects of Different Medical Marijuana Strains on Motor and Cognitive Function in People With Multiple Sclerosisdecides the statusStopped, other reason
Phase 2/3 · 2017 · Placebo-controlled · MSFT-NCT03172741
Other linked trials: 9
These linked trials do not set the status.
Phase 2 · 2025 · Not randomised
- The effect of medical cannabis on neuropathic pain and spasticity in patients with MS and SCIMissed main goal
Phase 2 · 2018 · Placebo-controlled
- ECP002A (Δ9-THC) in MS patientsNo result found
Phase 2 · 2010 · Placebo-controlled
- Cannabis for Spasticity in Multiple SclerosisStopped, other reason
Phase 1/2 · 2004 · Placebo-controlled
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-28First listed as Being tested
Related hypotheses
- Spasticity: improve symptoms or function in MS (type not specified)
- Arbaclofen: improve symptoms or function in MS (type not specified)
- Baclofen: improve symptoms or function in MS (type not specified)
- Botulinum toxin type a: improve symptoms or function in MS (type not specified)
- Cannabidiol: improve symptoms or function in MS (type not specified)
- Dronabinol: improve symptoms or function in relapsing and progressive MS
- Dronabinol: improve symptoms or function in secondary progressive MS
- Nabilone: improve symptoms or function in MS (type not specified)
- Nabiximols: improve symptoms or function in MS (type not specified)
- Onabotulinumtoxina: improve symptoms or function in MS (type not specified)
- Rimabotulinumtoxinb: improve symptoms or function in MS (type not specified)
- Tizanidine: improve symptoms or function in MS (type not specified)
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error